O'Hanlon Terrance P, Carrick Danielle Mercatante, Arnett Frank C, Reveille John D, Carrington Mary, Gao Xiaojiang, Oddis Chester V, Morel Penelope A, Malley James D, Malley Karen, Dreyfuss Jonathan, Shamim Ejaz A, Rider Lisa G, Chanock Stephen J, Foster Charles B, Bunch Thomas, Plotz Paul H, Love Lori A, Miller Frederick W
From National Institute of Environmental Health Sciences (TPO, DMC, EAS, LGR, FWM), Center for Information Technology (JDM, JD), National Cancer Institute (SJC, CBF), and National Institute of Arthritis and Musculoskeletal Disease (PHP), National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; University of Texas-Houston Health Science Center (FCA, JDR), Houston, Texas; Basic Research Program (MC, XG), SAIC Frederick National Cancer Institute, Frederick, Maryland; University of Pittsburgh School of Medicine (CVO, PAM), Pittsburgh, Pennsylvania; Malley Research Programming Inc (KM), Rockville, Maryland; Mayo Clinic (TB), Rochester, Minnesota; and United States Food and Drug Administration (LAL), Rockville, Maryland.
Medicine (Baltimore). 2005 Nov;84(6):338-349. doi: 10.1097/01.md.0000189818.63141.8c.
The idiopathic inflammatory myopathies (IIM) are systemic connective tissue diseases in which autoimmune pathology is suspected to promote chronic muscle inflammation and weakness. We have performed low to high resolution genotyping to characterize the allelic profiles of HLA-A, -B, -Cw, -DRB1, and -DQA1 loci in a large population of North American Caucasian patients with IIM representing the major clinicopathologic groups (n = 571). We confirmed that alleles of the 8.1 ancestral haplotype were important risk markers for the development of IIM, and a random forests classification analysis suggested that within this haplotype, HLA-B0801, DRB10301 and/ or closely linked genes are the principal HLA risk factors. In addition, we identified several novel HLA factors associated distinctly with 1 or more clinicopathologic groups of IIM. The DQA10201 allele and associated peptide-binding motif (KLPLFHRL) were exclusive protective factors for the CD8+ T cell-mediated IIM forms of polymyositis (PM) and inclusion body myositis (IBM) (pc < 0.005). In contrast, HLA-A68 alleles were significant risk factors for dermatomyositis (DM) (pc = 0.0021), a distinct clinical group thought to involve a humorally mediated immunopathology. While the DQA10301 allele was detected as a possible risk factor for IIM, PM, and DM patients (p < 0.05), DQA103 alleles were protective factors for IBM (pc = 0.0002). Myositis associated with malignancies was the most distinctive group of IIM wherein HLA Class I alleles were the only identifiable susceptibility factors and a shared HLA-Cw peptide-binding motif (AGSHTLQWM) conferred significant risk (pc = 0.019). Together, these data suggest that HLA susceptibility markers distinguish different myositis phenotypes with divergent pathogenetic mechanisms. These variations in associated HLA polymorphisms may reflect responses to unique environmental triggers resulting in the tissue pathospecificity and distinct clinicopathologic syndromes of the IIM.
特发性炎性肌病(IIM)是一类系统性结缔组织疾病,怀疑其自身免疫病理机制会引发慢性肌肉炎症和肌无力。我们对大量代表主要临床病理类型的北美白种IIM患者(n = 571)进行了低分辨率至高分辨率基因分型,以表征HLA - A、- B、- Cw、- DRB1和 - DQA1基因座的等位基因谱。我们证实8.1祖先单倍型的等位基因是IIM发病的重要风险标志物,随机森林分类分析表明,在该单倍型中,HLA - B0801、DRB10301和/或紧密连锁基因是主要的HLA风险因素。此外,我们还鉴定出了几种与IIM的1个或多个临床病理类型明显相关的新型HLA因素。DQA10201等位基因及相关肽结合基序(KLPLFHRL)是CD8 + T细胞介导的IIM形式的多发性肌炎(PM)和包涵体肌炎(IBM)的专属保护因素(pc < 0.005)。相比之下,HLA - A68等位基因是皮肌炎(DM)的显著风险因素(pc = 0.0021),DM是一个被认为涉及体液介导免疫病理机制的独特临床类型。虽然DQA10301等位基因被检测为IIM、PM和DM患者的可能风险因素(p < 0.05),但DQA103等位基因是IBM的保护因素(pc = 0.0002)。与恶性肿瘤相关的肌炎是IIM中最具特色的类型,其中HLA I类等位基因是唯一可识别的易感因素,一个共享的HLA - Cw肽结合基序(AGSHTLQWM)带来显著风险(pc = 0.019)。总之,这些数据表明HLA易感标志物区分了具有不同致病机制的不同肌炎表型。这些相关HLA多态性的差异可能反映了对独特环境触发因素的反应,从而导致IIM的组织病理特异性和独特的临床病理综合征。